At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZEAL Zealand Pharma A/S
Not Yet Opened 10-25 16:00:00 EDT
17.59
+0.00
0.00%
High17.59Low17.59Vol0.00
Open17.59D1 Closing17.59Amplitude0.00%
Mkt Cap814.08MTradable Cap647.26MTotal Shares46.28M
T/O0.00T/O Rate0.00%Tradable Shares36.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Zealand Pharma Fails to Get FDA Approval for Short Bowel Syndrome Drug
MT Newswires Live  ·  12-20
Zealand Pharma Fails to Get FDA Approval for Short Bowel Syndrome Drug
ZEAL Network’s Upgraded Financial Guidance and Buy Rating Amid Revenue and EBITDA Growth
TIPRANKS  ·  12-19
ZEAL Network’s Upgraded Financial Guidance and Buy Rating Amid Revenue and EBITDA Growth
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire  ·  11-12
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
ZEAL Network: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating
TIPRANKS  ·  10-25
ZEAL Network: Strong Q3 Performance and Upgraded Guidance Justify Buy Rating
Zealand Pharma Boehringer Receives FDA Breakthrough Therapy Designation For Survodutide
T-Reuters  ·  10-08
Zealand Pharma Boehringer Receives FDA Breakthrough Therapy Designation For Survodutide
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
GlobeNewswire  ·  09-30
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire  ·  09-12
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight
MT Newswires Live  ·  09-09
Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight
Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight
MT Newswires Live  ·  09-09
Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight
Zealand Pharma Announces Positive Topline Results From 13-Week Phase 1B Multiple Ascending Dose Clinical Trial With Glp-1/Glp-2 Receptor Dual Agonist Dapiglutide
T-Reuters  ·  09-09
Zealand Pharma Announces Positive Topline Results From 13-Week Phase 1B Multiple Ascending Dose Clinical Trial With Glp-1/Glp-2 Receptor Dual Agonist Dapiglutide
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
GlobeNewswire  ·  08-31
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
GlobeNewswire  ·  08-30
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire  ·  08-23
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
ZEAL Network (0QJQ) Receives a Buy from Berenberg Bank
TIPRANKS  ·  08-15
ZEAL Network (0QJQ) Receives a Buy from Berenberg Bank
Warburg Research Sticks to Its Buy Rating for ZEAL Network (0QJQ)
TIPRANKS  ·  08-03
Warburg Research Sticks to Its Buy Rating for ZEAL Network (0QJQ)
Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
seekingalpha  ·  07-25
Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
ZEAL Network’s Strategic Moves and Financial Upswing Prompt Buy Rating
TIPRANKS  ·  07-15
ZEAL Network’s Strategic Moves and Financial Upswing Prompt Buy Rating
ZEAL NETWORK SE : JEFFERIES RAISES TARGET PRICE TO EUR 45 FROM EUR 39
THOMSON REUTERS  ·  07-15
ZEAL NETWORK SE : JEFFERIES RAISES TARGET PRICE TO EUR 45 FROM EUR 39

Introduction

Company Name.
Zealand Pharma A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Issue price:
--